Objective: In this review, we summarize ongoing clinical trials involving liquid biopsies (LB) for colorectal cancer (CRC), outlining the current landscape and the future implementation of this technology. We also describe the current use of LB in CRC treatment at our institution, the Mayo Clinic Enterprise. Background: The use of LB in CRC treatment merits close attention. Their role is being evaluated in the screening, non-intervention, intervention, and surveillance settings through many active trials. This, coupled with the technique's rapid integration into clinical practice, creates constant evolution of care. Methods: Review of ClinicalTrials.gov was performed identifying relevant and active trials involving LB for CRC. "Colorectal cancer" plus other terms including "liquid biopsies" and "ctDNA" were used as search terms, identifying 35 active trials. Conclusions: LB use for the CRC is actively being investigated and requires close attention. Based on current evidence, Mayo Clinic Enterprise currently uses LB in the non-interventional, interventional and surveillance setting, but not for screening. Results of these trials may further establish the use of LB in the management of CRC. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Objective: In this review, we summarize ongoing clinical trials involving liquid biopsies (LB) for colorectal cancer (CRC), outlining the current landscape and the future implementation of this technology. We also describe the current use of LB in CRC treatment at our institution, the Mayo Clinic Enterprise. Background: The use of LB in CRC treatment merits close attention. Their role is being evaluated in the screening, non-intervention, intervention, and surveillance settings through many active trials. This, coupled with the technique's rapid integration into clinical practice, creates constant evolution of care. Methods: Review of ClinicalTrials.gov was performed identifying relevant and active trials involving LB for CRC. "Colorectal cancer" plus other terms including "liquid biopsies" and "ctDNA" were used as search terms, identifying 35 active trials. Conclusions: LB use for the CRC is actively being investigated and requires close attention. Based on current evidence, Mayo Clinic Enterprise currently uses LB in the non-interventional, interventional and surveillance setting, but not for screening. Results of these trials may further establish the use of LB in the management of CRC. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Liquid biopsy; clinical trial; colorectal cancer (CRC)
Authors: Scott V Bratman; S Y Cindy Yang; Marco A J Iafolla; Zhihui Liu; Aaron R Hansen; Philippe L Bedard; Stephanie Lheureux; Anna Spreafico; Albiruni Abdul Razak; Svetlana Shchegrova; Maggie Louie; Paul Billings; Bernhard Zimmermann; Himanshu Sethi; Alexey Aleshin; Dax Torti; Kayla Marsh; Jenna Eagles; Iulia Cirlan; Youstina Hanna; Derek L Clouthier; Scott C Lien; Pamela S Ohashi; Wei Xu; Lillian L Siu; Trevor J Pugh Journal: Nat Cancer Date: 2020-08-03
Authors: Qu Zhang; Jia Luo; Han Si; Shaad E Abdullah; Brandon W Higgs; Todd Hembrough; Song Wu; Chen Gao; Wenjing Xu; Phillip A Dennis; Michiel S van der Heijden; Neil H Segal; Jamie E Chaft; J Carl Barrett; Matthew D Hellmann Journal: Cancer Discov Date: 2020-08-14 Impact factor: 39.397
Authors: Pieter A Boonstra; Thijs T Wind; Michel van Kruchten; Ed Schuuring; Geke A P Hospers; Anthonie J van der Wekken; Derk-Jan de Groot; Carolien P Schröder; Rudolf S N Fehrmann; Anna K L Reyners Journal: Cancer Metastasis Rev Date: 2020-09 Impact factor: 9.264
Authors: Clinton L Cario; Emmalyn Chen; Lancelote Leong; Nima C Emami; Karen Lopez; Imelda Tenggara; Jeffry P Simko; Terence W Friedlander; Patricia S Li; Pamela L Paris; Peter R Carroll; John S Witte Journal: BMC Cancer Date: 2020-08-28 Impact factor: 4.430